If you have been reading about REV-ERB agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-12. Numbers and descriptions here follow the published literature rather than marketing material.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
Epicatechin gallate (ECG, (−)-epicatechin-3-gallate) is a flavan-3-ol, a type of flavonoid, primarily found in green tea (Camellia sinensis), with smaller amounts in cocoa, grapes, buckwheat, and other plants. It is not a nutrient. As a polyphenolic catechin, ECG is formed by the esterification of epicatechin with gallic acid. ECG is studied for its ability to reverse methicillin resistance in Staphylococcus aureus, but it has poor bioavailability and thermal instability in boiling water.
Nucleonica nuclear science portal Nucleonica's Decay Engine for professional online decay calculations EPA – Radioactive Decay Government website listing isotopes and decay energies National Nuclear Data Center – freely available databases that can be used to check or construct decay chains IAEA – Live Chart of Nuclides (with decay chains) Decay Chain Finder
In 2000, the World Health Organization redefined "carcinoid", but this new definition has not been accepted by all practitioners. This has led to some complexity in distinguishing between carcinoid and other neuroendocrine tumors in the literature. According to the American Cancer Society, the 2000 WHO definition states: The WHO now divides these growths into neuroendocrine tumors and neuroendocrine cancers. Neuroendocrine tumors are growths that look benign but that might possibly be able to spread to other parts of the body. Neuroendocrine cancers are abnormal growths of neuroendocrine cells which can spread to other parts of the body.
=== Secretariat === The commission is serviced by a Secretariat headed by a Secretary with four Additional Secretaries, several Joint Secretaries, Deputy Secretaries, and other supporting staff. The secretariat, for administrative purposes, is further divided into divisions, each undertaking having a specific responsibility:
Sources: en.wikipedia.org
== External links == ImmPort - Gene summaries, ontologies, pathways, protein/protein interactions and more for genes involved in antigen processing and presentation antigen+presentation at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
=== Generic names === Nandrolone is the generic name of the drug and its INNTooltip International Nonproprietary Name, BANTooltip British Approved Name, DCFTooltip Dénomination Commune Française, and DCITTooltip Denominazione Comune Italiana. The formal generic names of nandrolone esters include nandrolone cyclohexylpropionate (BANMTooltip British Approved Name), nandrolone cyclotate (USANTooltip United States Adopted Name), nandrolone decanoate (USANTooltip USAN, USPTooltip United States Pharmacopeia, BANMTooltip British Approved Name, JANTooltip Japanese Accepted Name), nandrolone laurate (BANMTooltip British Approved Name), nandrolone phenpropionate (USPTooltip United States Pharmacopeia), and nandrolone phenylpropionate (BANMTooltip British Approved Name, JANTooltip Japanese Accepted Name).
Ovaleap was approved for medical use in the European Union in September 2013. It was approved for medical use in Australia in March 2021. Bemfola was approved for medical use in the European Union in March 2014.
== History == The Inner London Education Authority was established when the Greater London Council (GLC) replaced the London County Council (LCC) as the principal local authority for London in 1965. The LCC had, in 1904, taken over from the London School Board responsibility for education in Inner London. In what was to become Outer London, education was during the first half of the twentieth century primarily administered by the relevant county councils and county boroughs, with some functions delegated to second-tier councils in the area. The Herbert Commission report in 1960 recommended the establishment of the Greater London Council. It advocated a London-wide division of educational powers between the GLC and the London boroughs. The GLC would be responsible for strategic control of schools, and the boroughs for routine management. This part of the report was rejected by the government. Councils in the future Outer London area wanted greater control over education, preventing the creation of a London-wide local education authority (LEA), and there was strong opposition from teachers and other bodies to the idea of dividing up the LCC LEA. The London Government Act 1963 therefore created the ILEA to inherit the educational responsibilities of the LCC, and gave Outer London boroughs LEA status. The ILEA was originally conceived as a provisional body whose status would be reviewed before 1970, but the Labour government made its status permanent in 1965. The ILEA did not cover the small area of North Woolwich, where the LCC had provided a secondary school.
Kennedy decided toward the end of 1871 to end his business partnership with Eddy. She had accused him in front of others of cheating at cards; it was one of several scenes she had caused between them and he walked out on her. There was a temporary reconciliation, but he was unhappy about the abandonment of head rubbing, and after a dispute between Eddy and a student over a refund was played out in the local press, he decided to go his own way. Once Kennedy and Eddy had settled their financial affairs in May 1872, she was left with $6,000. Peel writes that at this point she had already written 60 pages of Science and Health. She was renting rooms in Lynn at 9 Broad Street, when 8 Broad Street came on the market. In March 1875 she purchased it for $5,650, taking in students to pay the mortgage. It was in the attic room of this house that she completed Science and Health. Shortly after moving in, Eddy became close to another student, Daniel Spofford. He was 33 years old and married when he joined her class; he later left his wife in the hope that he might marry Eddy, but his feelings were not reciprocated. Spofford and seven other students agreed to form an association that would pay Eddy a certain amount a week if she would preach to them every Sunday. They called themselves the Christian Scientists' Association. Eddy placed a sign on 8 Broad Street: "Mary B.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.